课题基金 / 基金详情

New parenteral formulation of Celecoxib for the management of postoperative pain

New parenteral formulation of Celecoxib for the management of postoperative pain
用于治疗术后疼痛的新型塞来昔布肠外制剂
批准号:
533940-2018
负责人:
Fortier, Isabelle
金额:
$1.82万
依托单位:
依托单位国家:
加拿大
项目类别:
Applied Research and Development Grants - Level 1
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-01-01 至 2019-12-31

项目摘要

项目成果

Fortier, Isabelle的其他基金

相似基金

相关文献

中文摘要
翻译
最近的研究强调了COX2抑制剂作为阿片类药物治疗术后疼痛的替代品的价值,特别是塞来昔布的使用。由于西乐葆的水溶性很低,只能以片剂的形式使用,因此不能在手术期间和手术后立即使用片剂。Altus是一家专门从事创新给药系统开发的制药公司。在他们的各种给药平台中,smartcell技术使高不溶性药物的肠外给药成为可能。先前的动物研究强调了该技术的潜力,因为结果证明了该方法的多功能性和耐受性。该项目旨在开发和验证术后疼痛模型,以评估新型镇痛制剂的效力,并评估塞来昔布注射制剂在动物模型中的效力。TransBIOTech将首先通过测量动物对机械刺激的敏感性来评估目前使用的注射镇痛药丁丙诺啡和酮罗拉酸对大鼠足底切口疼痛模型的反应。之后,新型注射制剂塞来昔布的效力将在足底切口模型中进行评估,并与酮罗拉克进行比较。****
英文摘要
Recent studies have highlighted the value of COX2 inhibitors as alternatives to opioids for the management of postoperative pain and, in particular, the use of Celecoxib. Due to its very low water solubility Celebrex is only available in tablet, precluding its use during and immediately after surgery when tablet formulations cannot be administered. Altus Formulation is a pharmaceutical company specialized in the development of innovative drug delivery systems. Among their various delivery platforms, the SmartCelle technology enables the parenteral delivery of highly insoluble drugs. Previous animal studies have highlighted the potential of the technology as results demonstrated the versatility and the tolerability of the approach. This project aims to develop and validate a postoperative pain model to evaluate the potency of novel analgesic formulations and to assess the potency of an injectable formulation of Celecoxib in the animal model. TransBIOTech will first evaluate the response to currently use injectable analgesics, buprenorphin and Ketorolac of the plantar incision pain model in the rat by measuring the sensitivity of the animals to mechanical stimulation. Afterward, the potency of the novel injectable formulation of Celecoxib will be evaluated in the plantar incision model and compared to Ketorolac.****
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of topical formulations for the treatment of basal cell carcinoma using the Feldan Shuttle technology
  • 批准号:
    549971-2020
  • 项目类别:
    Applied Research and Development Grants - Level 3
  • 资助金额:
    $9.11万
  • 财政年份:
    2021
  • 负责人:
    Fortier, Isabelle
  • 依托单位:
Analyses UPLC-TOF d'échantillons de salive, d'urine et de sang séchés en vue de caractérisation métabolomique non-ciblée
  • 批准号:
    560784-2020
  • 项目类别:
    Applied Research and Development Grants - Level 1
  • 资助金额:
    $1.82万
  • 财政年份:
    2021
  • 负责人:
    Fortier, Isabelle
  • 依托单位:
Bioavailability evaluation of new innovative formulations
  • 批准号:
    562749-2021
  • 项目类别:
    Engage Plus Grants for Colleges
  • 资助金额:
    $0.91万
  • 财政年份:
    2021
  • 负责人:
    Fortier, Isabelle
  • 依托单位:
Renouvellement de la subvention ECAT (2017-2022) pour le maintien en poste d'un directeur scientifique, gestionnaire de la recherche à TrasnsBIOTech
  • 批准号:
    411543-2017
  • 项目类别:
    Technology Access Centre
  • 资助金额:
    $0.09万
  • 财政年份:
    2021
  • 负责人:
    Fortier, Isabelle
  • 依托单位:
海外基金